Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

RIDGEFIELD, Conn., Feb. 20, 2025 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S ...

Boehringer Ingelheim has a new president of U.S. human pharma in Brian Hilberdink, who joins from his previous role as executive vice president at LEO Pharma. At LEO, Hilberdink worked as head of ...

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

These agencies work closely with the pharma industry to create content and support their efforts in bringing treatments to market. Traditionally, these agencies have relied heavily on human ...

MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving ...